Swiss eyecare firm Alcon has made a move to boost its position in ophthalmological medicines with a $15.25 per share offer to buy Aerie Pharmaceuticals in a transaction that values the US company ...

Alcon Inc.’s ALC growth in the third quarter ... respectively. The renowned pharmaceutical and medical device manufacturer has a market capitalization of $42.63 billion. ALC’s earnings ...

Tarsus Pharmaceuticals (NASDAQ:TARS) has pared some of an earlier gain of as much as 13% and is now up 8% amid a report that ...

UNITED STATES - Alcon Laboratories has issued a recall for a specific lot of its 'Systane Lubricant Eye Drops Ultra P-F' due to potential fungal contamination. This recall follows a consumer ...

Alcon, Inc. engages in the development, manufacture, and marketing of market surgical equipment and devices, pharmaceutical eye drops, and consumer vision care products to treat eye diseases and ...

Alcon Laboratories is also notifying its distributors ... are sold under the brand names Equate, CVS Health and AACE Pharmaceuticals, and have expiration dates ranging from February 2024 to ...

The eye-care company Alcon Research has entered into licensing and purchase option agreements with Potentia Pharmaceuticals to develop Potentia's leading drug candidate — a complement pathway ...

The global ophthalmic sprays market, valued at USD 343 million in 2023, is projected to experience exponential growth, reaching a remarkable USD 783.3 million by 2033. This growth is underpinned by a ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Forte Biosciences (FBRX – Research Report) and ...